Recibokibart Biosimilar Monoclonal Antibody (IL-36R) for Research

Cat No.: GMP-Bios-INN-1359

Anti-IL1RL2/IL1Rrp2/IL1RRP2/IL-36R/IL36R therapeutic antibody (Pre-made Recibokibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Recibokibart (development code HB0034) is a humanized monoclonal antibody targeting IL1RL2. It is developed by Shanghai Huaota Biopharmaceutical Co., Ltd. for Pustular psoriasis, Systemic lupus erythematosus, Ulcerative colitis in Phase II/III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1359-1mg 1mg 3090
GMP-Bios-INN-1359-10mg 10mg
GMP-Bios-INN-1359-100mg 100mg
GMP-Bios-INN-1359-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Recibokibart biosimilar, Whole mAb, Anti-IL1RL2/IL1Rrp2/IL1RRP2/IL-36R/IL36R Antibody: Anti-IL-36R/IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody
INN Name Recibokibart
Target IL1RL2/IL1Rrp2/IL1RRP2/IL-36R/IL36R
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II/III
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies TBC
Conditions Approved na
Conditions Active na
Conditions Discontinued Pustular psoriasis;Systemic lupus erythematosus;Ulcerative colitis
Production na
Development Tech na